Patients diagnosed with cancer often experience pain during their treatment course, making
it difficult to care for themselves and continue with their activities of daily living. When cancer …

We performed a systematic review and meta-analysis of randomised controlled trials (RCTs)
conducted from January 2005 to June 2021 to update the evidence of Botulinum toxin A …

Botulinum neurotoxins (BoNTs) are potent inhibitors of synaptic vesicle fusion and
transmitter release. The natural target of BoNTs is the peripheral neuromuscular junction …

Simple Summary This review discusses treatment approaches for providing pain relief to
oncological patients affected by pain caused by nerve damage due to the tumor, also known …

Abstract Purpose of Review Breast cancer is currently the most prevalent cancer diagnosed
globally, and there is a significant gap in the availability of effective first-line treatment …

Xeomin® is a commercial formulation of botulinum neurotoxin type A (BoNT/A) clinically
authorized for treating neurological disorders, such as blepharospasm, cervical dystonia …

A majority of older patients suffer from neuropathic pain (NP) that significantly alters their
daily activities and imposes a significant burden on health care. Multiple comorbidities and …

Context Patients with chronic pelvic pain syndrome (CPPS) may have pain refractory to
conventional management strategies. Botulinum toxin A (BTX-A) is a potential therapeutic …

Although botulinum toxin (BoNT) has been suggested as a treatment to counter neuropathic
pain, no previous systematic reviews investigated the multidimensional effects of BoNT on …

The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic
complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications …